World’s first dengue vaccine, named as Dengvaxia, has been approved by 14 countries including Indonesia, Thailand and Singapore.
Till date, the vaccine is approved in Mexico, The Philippines, Brazil, El Salvador, Costa Rica, Paraguay, Guatemala, Peru, Indonesia, Thailand and Singapore.
The vaccine Dengvaxia is said to prevent two-thirds of dengue cases and also prevented 8 of 10 hospitalizations due to disease over the 25-month study follow-up period.
The vaccine was developed by Sanofi Pasteur. According to WHO, it was first licensed in Mexico in December 2015 for use in individuals 9-45 years of age living in endemic areas. It is given as a 3-dose series on a 0/6/12 month schedule. “We’re pleased to see the growing medical and public health recognition for the vaccine. With this new tool in hand, public health communities in dengue-endemic countries now have additional means to achieve the WHO objectives for 50 per cent reduction in mortality and 25 per cent reduction in morbidity due to dengue by 2020,” Su Peing Ng, head of Global Medical Affairs for Sanofi Pasteur, said in a statement.
Dengue is a mosquito-borne tropical disease having symptoms like high fever, headache, vomiting, muscle and joint pains amongst others.
Generally, recovery takes less than two to seven days. However, in some cases, the disease develops into the life-threatening
dengue hemorrhagic fever, resulting in bleeding, low levels of blood platelets or even death.
This year, PTI reported that at least 21 deaths due to dengue were reported at various hospitals, including nine at AIIMS, in the national capital. Also, d
engue cases crossed the 2,100 mark in the city.